Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
40 studies found for:    "Vatalanib"
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Vatalanib;   Drug: Gemcitabine
2 Completed PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia;   Agnogenic Myeloid Metaplasia;   Chronic Myelogenous Leukemia
Interventions: Drug: Imatinib Mesylate (Gleevec);   Drug: PTK 787 (vatalanib)
3 Completed
Has Results
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Conditions: Brain and Central Nervous System Tumors;   Sarcoma
Intervention: Drug: vatalanib
4 Completed
Has Results
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: vatalanib
5 Terminated PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Intervention: Drug: PTK787
6 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
7 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
8 Completed Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Conditions: Ovarian Cancer;   Endometrial Cancer;   Cervical Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Cancer
Interventions: Drug: Docetaxel;   Drug: PTK787
9 Completed Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: hydroxyurea;   Drug: imatinib mesylate;   Drug: vatalanib
10 Completed PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Condition: Sarcoma
Intervention: Drug: PTK787/ZK222584
11 Active, not recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Melanoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pheochromocytoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging
12 Unknown  Trial of PTK787/ZK 222584 Plus Paclitaxel
Condition: Metastatic Non-hematologic Malignancies
Interventions: Drug: PTK787/ZK 222584;   Drug: paclitaxel
13 Completed Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Conditions: Kidney Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: RAD001 (everolimus);   Drug: PTK787 (vatalanib)
14 Completed Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Conditions: Tumors;   Neoplasm Metastasis
Intervention: Drug: PTK787/ZK 222584 (vatalanib)
15 Completed Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PTK787
16 Active, not recruiting Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vatalanib;   Drug: pemetrexed disodium;   Other: pharmacological study;   Procedure: ultrasound imaging
17 Completed Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Condition: Wet Age-Related Macular Degeneration
Interventions: Drug: PTK787;   Drug: Placebo
18 Completed PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Conditions: Refractory Malignancy;   Advanced Malignancies
Intervention: Drug: PTK787/ZK222584 and Bevacizumab
19 Completed Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
Intervention: Drug: vatalanib
20 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years